Induced Pluripotent Stem Cells Market Exclusive insight on Transformation 2029 Clark County Blog – Clark County Blog

Induced pluripotent stem cells (iPSCs) hold profound potential in replacing the use of embryonic stem cells (ESCs) as important tool for drug discovery and development, disease modeling, and transplantation medicine. Advent of new approaches in reprogramming of somatic cells to produce iPSCs have considerably advanced stem cell research, and hence the induced pluripotent stem cells market. The iPSC technology has shown potential for disease modeling and gene therapy in various areas of regenerative medicine. Notable candidates are Parkinsons disease, spinal cord trauma, myocardial infarction, diabetes, leukemia, and heart ailments.

Get Sample Copy of the Report @

Over the past few years, researchers have come out with several clinically important changes in reprogramming process; a case in point is silencing retroviruses in the human genome. Molecular mechanisms that underlie reprogramming have gained better understanding. However, the tools based on this growing understanding are still in nascent stage. Several factors affect the efficiency of reprogramming, most notably chromosomal instability and tumor expression. These have hindered researchers to utilize the full therapeutic potential of iPSCs, reflecting an unmet need, and hence, a vast potential in the induced pluripotent stemcellsmarket.

The growing application of induced pluripotent stem cells in generating patient-specific stem cells for drug development and human disease models is a key dynamic shaping their demands. Growing focus on personalized regenerative cell therapies among medical researchers and healthcare proponents in various countries have catalyzed their scope of induced pluripotent stem cells market. Advent of new methods to induce safe reprogramming of cells have helped biotechnology companies improve the clinical safety and efficacy of the prevailing stem cells therapies. The relentless pursuit of alternative source of cell types for regenerative therapies has led industry players and the research fraternity to pin hopes on iPSCs to generate potentially a wide range of human cell types with therapeutic potential.

Advances pertaining to better utilizing of retrovirus and lentivirus as reprogramming transcription factors in recent years have expanded the avenue for players in the induced pluripotent stem cells market. Increasing focus on decreasing the clinical difference between ESCs and iPSCs in all its entirety has shaped current research in iPSC technologies, thus unlocking new, exciting potential for biotechnology and pharmaceutical industries.

Over the past few years, fast emerging markets in the global induced pluripotent stem cells are seeing the advent of patents that unveil new techniques for reprogramming of adult cells to reach embryonic stage. Particularly, the idea that these pluripotent stem cells can be made to form any cells in the body has galvanized companies to test their potential in human cell lines. Also, a few biotech companies have intensified their research efforts to improve the safety of and reduce the risk of genetic aberrations in their approved human cell lines. Recently, this has seen the form of collaborative efforts among them.

Lineage Cell Therapeutics and AgeX Therapeutics have in December 2019 announced that they have applied for a patent for a new method for generating iPSCs. These are based on NIH-approved human cell lines, and have been undergoing clinical-stage programs in the treatment of dry macular degeneration and spinal cord injuries. The companies claim to include multiple techniques for reprogramming of animal somatic cells.

Such initiatives by biotech companies are expected to impart a solid push to the evolution of the induced pluripotent stem cells.

North America is one of the regions attracting colossal research funding and industry investments in induced pluripotent stem cells technologies. Continuous efforts of players to generate immune-matched supply of pluripotent cells to be used in disease modelling has been a key accelerator for growth. Meanwhile, Asia Pacific has also been showing a promising potential in the expansion of the prospects of the market. The rising number of programs for expanding stem cell-based therapy is opening new avenues in the market.

Request TOC of the Report @

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.


TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050

Read more:

Induced Pluripotent Stem Cells Market Exclusive insight on Transformation 2029 Clark County Blog - Clark County Blog

Read more
Mesenchymal Stem Cells Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players Analysis- Lonza,…

Industry Growth Insights (IGI) published a detailed report on Global Mesenchymal Stem Cells Market for the clients that wants to explore new market avenues, get in-depth insights on the market products, maximize their revenue, and review the strategies implemented by prominent players in the market.

Key Players of the Mesenchymal Stem Cells Market

LonzaThermo FisherBio-TechneATCCMilliporeSigmaPromoCell GmbHGenlantisCelprogenCell ApplicationsCyagen BiosciencesAxol Bioscience

Get Sample of the Mesenchymal Stem Cells Report

Major Highlights of the Mesenchymal Stem Cells Market Report

The research team at Industry Growth Insights (IGI) has proximately monitored the market since 2017. During the time, the team has covered the factors that are expected to boost the market performance and impede the growth of the market during the forecast period, 2020-2027. Additionally, it has enlisted the challenges faced by key market players, new entrants, and emerging players in the market.

What is Covered in the Chapter of Impact of COVID-19 Pandemic?

The coronavirus pandemic has disrupted the market dynamics, as it had imposed the restriction on the opening of offices and manufacturing facilities. This, in turn, has persuaded employees to work from home and halted the production of goods across the globe. Moreover, it had increased the gap between demand and supply owing to the restricted trade affairs around the world. However, it has created lucrative opportunities for the key players in certain regions.

The COVID-19 chapter of Mesenchymal Stem Cells Market includes:

What is Covered in The Segmentation Part of The Mesenchymal Stem Cells Report?


Human MSCMouse MSCRat MSCOther


Research InstituteHospitalOthers


Note: Can add country of your choice in the report at no extra cost.

The segmentation part of the report covers:

This segmentation provides the esteemed reader with the comprehensive regional analysis, which includes if the region/country has a potential worth of investment. This analysis is prepared by considering the socio-economic development and government regulations & policies of the country.

Buy the Complete Report

Note: Additional company names can be added in the list.

The report covers the major players of the market and provides information about their product portfolio and strategies deploying regarding the market. This market report includes technological advancements of products by the key players. It lays out the information on collaborations, partnerships, mergers, and agreements carried out by industry players over the years in the market. Furthermore, it covers the factors that have created opportunities and challenges for them.

7 Reasons to Buy Report from Industry Growth Insights (IGI)

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Mesenchymal Stem Cells Market Overview

Global Mesenchymal Stem Cells Market Analysis and Forecast by Type

Global Mesenchymal Stem Cells Market Analysis and Forecast by Application

Global Mesenchymal Stem Cells Market Analysis and Forecast by Sales Channel

Global Mesenchymal Stem Cells Market Analysis and Forecast by Region

North America Mesenchymal Stem Cells Market Analysis and Forecast

Latin America Mesenchymal Stem Cells Market Analysis and Forecast

Europe Mesenchymal Stem Cells Market Analysis and Forecast

Asia Pacific Mesenchymal Stem Cells Market Analysis and Forecast

Asia Pacific Mesenchymal Stem Cells Market Size and Volume Forecast by Application

Middle East & Africa Mesenchymal Stem Cells Market Analysis and Forecast

Competition Landscape

If you have any inquiry of the report, connect with our analyst @

About Industry Growth Insights (IGI)

Industry Growth Insights (IGI) has extensive experience in the creation of tailored market research reports in several industry verticals. We cover in-depth market analysis which includes producing creative business strategies for the new entrants and the emerging players of the market. We take care that our every report goes through intensive primary, secondary research, interviews, and consumer surveys. Our company provides market threat analysis, market opportunity analysis, and deep insights into the current and market scenario.

To provide the utmost quality of the report, we invest in analysts that hold stellar experience in the business domain and have excellent analytical and communication skills. Our dedicated team goes through quarterly training which helps them to acknowledge the latest industry practices and to serve the clients with the foremost consumer experience.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 414 1393Email: [emailprotected]Website:

Read the rest here:

Mesenchymal Stem Cells Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players Analysis- Lonza,...

Read more
Placental Stem Cell Collection and Storage Market Key Business Opportunities, Impressive Growth Rate and Development Analysis to 2026 | Americord,…

Global Placental Stem Cell Collection and Storage Industry: with growing significant CAGR during 2021-2026

ThePlacental Stem Cell Collection and Storage Marketreport[5 Years Forecast 2021-2026]focuses on theCOVID19 Outbreak Impact analysisof key points influencing the growth of the market

ThePlacental Stem Cell Collection and Storage Market Global industry Analysis, Size, Share, Growth, Trends and Forecast, 20212026 report provides AN analysis of the Placental Stem Cell Collection and Storage Marketplace for the period 20212026, whereby 2020 to 2026 is that the forecast period and 2019 is taken into account because the base year. Information for 2016 has been enclosed as historical info. The report covers all the trends and technologies that play a serious role within the growth of the Placental Stem Cell Collection and Storage Market throughout the forecast period. It highlights the drivers, restraints and opportunities expected to influence the Markets enlargement throughout this era. The study provides a holistic perspective on the Markets growth in terms of revenue and volume (in US$ Mn and Units) across completely different nations that embody North America, Europe, Asia Pacific, Mideast & continent and South America. The report highlights key trends moving the Market on a worldwide scale. moreover, outstanding countries/regions coated within the report embody theU.S, Canada, U.K, Germany, France, Spain, Italy, Central/Eastern Europe, India, China, Japan, South Korea, GCC countries, Republic of South Africa and Brazil.

>>>Major Market Players indulged in this report are:

Americord, Pluristem TherapeuticsPSTI, Celularity, Cryobank, ReeLabs, China Cord Blood Corporation, Mesoblast Limited, Americord Registry, LifebankUSA, Ocata Therapeutics, Stemcyte, Cryoviva India, Caladrius Biosciences, H&B Group, Viacord, Cryo-Cell, CBR Systems, Inc., Cells4Life, Smart Cells International Ltd., Cordlife

The report analyzes and forecasts the Placental Stem Cell Collection and Storage Market at the worldwide and regional level. The report additionally contains a close worth chain analysis that provides a comprehensive read of the worldwide Placental Stem Cell Collection and Storage Market. Porters 5 Forces model has been enclosed to assist perceive the competitive landscape within the Market. The study encompasses Market attractiveness analysis, whereby end-users area unit benchmarked supported their Market size, rate of growth and general attractiveness.

Primary analysis involves e-mail interactions, telecommunication interviews and face-to-face interviews for every Market, category, segment and sub-segment across geographies. We tend to conduct primary interviews on an in progress basis with industry participants and commentators so as to validate the information and analysis. Primary interviews offer first-hand information on the Market size, Market trends, growth trends, competitive landscape, outlook, etc. These facilitate United States validate and strengthen secondary analysis findings. They additionally facilitate develop the analysis teams Market experience and understanding.

Placental Stem Cell Collection and Storage Market 2021 segments by product types:

Placental Subtopotent Stem CellsPlacental Hematopoietic Stem CellsPlacental Mesenchymal Stem Cells (MSC)Placental Maternal Pluripotent Stem Cells

The Application of the World Placental Stem Cell Collection and Storage Market 2021-2026 as follows:

Cell TherapyBeauty ProductsOther

Secondary analysis sources that area unit generally noted embody, however arent restricted to company websites, annual reports, money reports, broker reports, capitalist shows, SEC filings, internal and external proprietary databases, relevant patent and restrictive databases, national government documents, applied math databases, Market reports, news articles, press releases, webcasts specific to corporations in operation within the Market, national government documents, applied math databases, Market reports, Factiva, etc.

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2021 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

The Placental Stem Cell Collection and Storage Market report provides the Market competitive landscape and a corresponding elaborate analysis of the key vendor/key players within the Market. This report is split into four distinct components. The primary half consists of the introduction to the worldwide Placental Stem Cell Collection and Storage Market. Succeeding section consists of the worldwide Marketing research and forecast by material kind, by applications, by end-use industry and by region. The third half consists of a Marketing research and forecast. The last section of the report highlights the competitive landscape of the worldwide Placental Stem Cell Collection and Storage Market and provides the list of the vital players in operation during this moneymaking Market.

Key Questions Answered in This Report:

The study offers info concerning the business profiles of all the mentioned corporations. Information associated with the product factory-made by the companies is given within the report. Details concerning the applying also as specifications of the merchandise area unit inculcated within the report. Info associated with the expansion margins of the companies, producing expenses and products prices is provided within the report. The regional average rating analysis for the year 2021 is additionally mentioned here. Info concerning the worth chain analysis of the worldwide Placental Stem Cell Collection and Storage Market is additionally given during this section of the report.

Key Topics Covered:

1 Preface

2 Scope and Methodology2.1 Objectives of the Study2.2 Stakeholders2.3 Data Sources2.3.1 Primary Sources2.3.2 Secondary Sources2.4 Market Estimation2.5 Forecasting Methodology

3 Executive summary

4 Introduction4.1 Overview4.2 Key Industry Trends

5 Global Placental Stem Cell Collection and Storage Market5.1 Market Overview5.2 Market Performance5.3 Impact of COVID 195.4 Market Forecast

6 Market Breakup by Procedure Type

7 Market Breakup by Product

8 Market Breakup by Application

9 Market Breakup by Guidance Technique

10 Market Breakup by End User10.3.2 Market Forecast

11 Market Breakup by Region

12 SWOT Analysis12.1 Overview12.2 Strengths12.3 Weaknesses12.4 Opportunities12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

15 Price Indicators

16 Competitive Landscape

We offer Report Customization to meet your research requirement: Free country Level analysis for any 5 countries of your choice. Free Competitive analysis of any 5 key market players. Free 40 analyst hours to cover any other data point.

Top Key Players Mentioned:: Americord, Pluristem TherapeuticsPSTI, Celularity, Cryobank, ReeLabs

Get Free Sample Copy of this report:

Placental Stem Cell Collection and Storage Market CAGR Competitive Landscape, Market Research, Placental Stem Cell Collection and Storage Market Best Companies in The world , Placental Stem Cell Collection and Storage Market Top Companies in The world, Placental Stem Cell Collection and Storage Market Trend, Placental Stem Cell Collection and Storage Trends, Placental Stem Cell Collection and Storage growth, Placental Stem Cell Collection and Storage industry, Placental Stem Cell Collection and Storage Covid-19 Impact Analysis

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesPhone:+1 312-604-7084

View original post here:

Placental Stem Cell Collection and Storage Market Key Business Opportunities, Impressive Growth Rate and Development Analysis to 2026 | Americord,...

Read more
Animal Stem Cell Therapy Market Study Report and In-deep Analysis 2020 2026 The Courier – The Courier

Animal Stem Cell Therapy Market Size, Status, Business Future Scenarios and Brief Analysis 2020-2026

The report begins with the overview of the Animal Stem Cell Therapy Market and offers throughout development. It presents a comprehensive analysis of all the regional and major player segments that gives closer insights upon present market conditions and future market opportunities along with drivers, trending segments, consumer behavior, pricing factors and market performance and estimation. The forecast market information, SWOT analysis, Animal Stem Cell Therapy market scenario, and feasibility study are the vital aspects analyzed in this report.

The global stem cell therapy market is estimated to reach USD 210.66 million by 2026 from USD 65.5 million in 2019, at a CAGR of 11.4% during the forecast period 2020-2026.

Click the link to get a Sample Copy of the Report:

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Animal Stem Cell Therapy Market: MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics

Global Animal Stem Cell Therapy Market Split by Product Type and Applications:

This report segments the global Animal Stem Cell Therapy Market on the basis of Types are:




On the basis of Application, the Global Animal Stem Cell Therapy Market is segmented into:

Veterinary Hospitals

Research Organizations

Regional analysis of Global Animal Stem Cell Therapy Market:

The report provides a detailed breakdown of the market region-wise and categorizes it at various levels. Regional segment analysis displaying regional production volume, consumption volume, revenue, and growth rate from 2020-2026 covers: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia, Spain), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries). Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Any Query? Ask Our Experts:

What are the market factors that are explained in the report?

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

-Analytical Tools: The Global Animal Stem Cell Therapy Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

(Exclusive Offer: Up to 30% discount on this report)

Buy This Discount Report At:

Table of Content:

Animal Stem Cell Therapy Market Research Report 2020-2026

Chapter 1: Industry Overview

Chapter 2: Animal Stem Cell Therapy Market International and China Market Analysis

Chapter 3: Environment Analysis of Market.

Chapter 4: Animal Stem Cell Therapy Analysis of Revenue by Classifications

Chapter 5: Analysis of Revenue by Regions and Applications

Chapter 6: Analysis of Animal Stem Cell Therapy Market Revenue Market Status.

Chapter 7: Animal Stem Cell Therapy Analysis of Industry Key Manufacturers

Chapter 8: Sales Price and Gross Margin Analysis of Market.

Chapter 9: .Continue to TOC

About us:

The Research Insights A global leader in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact us:


Sales manager

Contact number: +91-996-067-0000

Read this article:

Animal Stem Cell Therapy Market Study Report and In-deep Analysis 2020 2026 The Courier - The Courier

Read more
Stem Cells Market to Witness Robust Expansion Throughout the Forecast Period 2018-2026 KSU | The Sentinel Newspaper – KSU | The Sentinel Newspaper

Coherent Market Insights released a new market study on 2018-2026 Stem Cells Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry-validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for the 2018-2026 Stem Cells Market Forecast till 2026*.

Get Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures)

Get Sample Copy Of this Research Report @

This research report also provides an overall analysis of the Stem Cells market share, size, segmentation, revenue forecasts and geographic regions of the Market along with industry-leading players are studied with product portfolio, capacity, price, cost and revenue. The research Stem Cells report analysis on the market current applications and comparative analysis with more focused on the pros and cons of and competitive analysis of major companies.

The Stem Cells Market report identifies the Market dynamics and trends within the global and regional Market considering numerous aspects including technology, supplies, capacity, production, profit, price and competition. Furthermore, this study highlights the company profiles and competitive landscape of the involved key players within the Stem Cells Market.

Synopsis Stem Cells Market Research Report covers insights of Stem Cells industry over the past five to eight years and forecasts until 2018-2026. Stem Cells Market report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Stem Cells Market 2018 Industry Trend and Forecast 2026

Stem Cells Market report provides key statistics on the market status of the Stem Cells manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Stem Cells industry. The Stem Cells Market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market.

Top Key Players of Stem Cells Market: Advanced Cell Technology, Inc., Angel Biotechnology Holdings PLC, Bioheart Inc., Lineage Cell Therapeutics., BrainStorm Cell Therapeutics, Inc., California Stem Cell Inc., Celgene Corporation, Takara Bio Europe AB, Cellular Engineering Technologies, Cytori Therapeutics Inc., Osiris Therapeutics, and STEMCELL Technologies Inc.

Regions of Stem Cells Market:

In the end, the report makes some important proposals for a new project of Stem Cells Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of the global Stem Cells industry covering all important parameters.

Stem Cells Driver Stem Cells Challenge Stem Cells Trends

Browse Stem Cells Research Report:Stem Cells Market

Further, in the Stem Cells Market research report, the following points are included along with an in-depth study of each point:

Production Analysis Production of the Stem Cells is analyzed with respect to different regions, types, and applications. Here, the price analysis of various Stem Cells Market key players is also covered.

Sales and Revenue Analysis Both, sales and revenue are studied for the different regions of the global Stem Cells Market. another major aspect, price, which plays an important part in the revenue generation is also assessed in this section for the various regions.

Supply and Consumption In continuation of sales, this section studies supply and consumption for the Stem Cells Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.

Other analyses Apart from the information, trade and distribution analysis for the Stem Cells Market, the contact information of major manufacturers, suppliers and key consumers are also given. Also, SWOT analysis for new projects and feasibility analysis for new investments are included.

In continuation with this data, the sale price is for various types, applications and regions is also included. The Stem Cells Market for major regions is given. Additionally, type-wise and application-wise consumption figures are also given.

The PDF Research only provides a Table of Contents (ToC), scope of the report and research framework of the report.

Get PDF Brochure Of this Research Report @

In this study, the years considered to estimate the market size of the 2018-2026 Stem Cells Market are as follows:

History Year: 2015-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2026

Originally posted here:

Stem Cells Market to Witness Robust Expansion Throughout the Forecast Period 2018-2026 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper

Read more
Global Cord Blood Stem Cells Market to 2026 Industry Perspective, Comprehensive Analysis, and Forecast KSU | The Sentinel Newspaper – KSU | The…

SMR Market Research announces the release of theCord Blood Stem Cells Marketresearch report. The market is predicted to grow at a healthy pace in the coming years. Cord Blood Stem Cells Market 2021 research report presents an analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market. The Market report offers remarkable data regarding the industrys growth parameters, the current state of the market in terms of analysis of possible economic situations, and macroeconomic analysis.

Sample Report with Latest Industry Trends @

Note-In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

The top companies in this report include:

Advanced Cell Technology, California Stem Cell, Cytori Therapeutics, Mesoblast Limited, Opexa Therapeutics Inc., Athersys Inc., Geron Corporation, Neostem Inc., CBR Systems Inc., Cordlife, Cryo-Cell, Cryo-Save AG (A Group of Esperite), Lifecell, Stemcyte,

Market split by Type can be divided into:

Allogeneic Stem Cell, Autologous Stem Cell

Market split by Application can be divided into:

Autoimmune Diseases, Immunodeficiencies, Malignancies,Caners, Solid Tumors, Others

This report provides an in-depth review of the current state of the Cord Blood Stem Cells market, daring its growth and all other essential elements in all of the major markets of the county. It presents a gigantic amount of market data, compiled using myriad primary and secondary research practices.

The data in this report has been reduced on a business basis using various systematic methods. For a comprehensive analysis, the Cord Blood Stem Cells market is segmented by product type, region, and application. Due to its regional focus, the market is alien to North America, Europe, Asia-Pacific, the Middle East, and Africa as well as Latin America. Major companies are working on distributing their products and services across different regions. In addition, procurements and associations from some of the leading organizations. All of the factors intended to drive the global marketplace are examined in depth.

Key Factors Impacting Market Growth:

Get Impressive Discount @

This report gives an in-depth and broad understanding of the Cord Blood Stem Cells Market. With exact data cover all key features of the current market, this report offers widespread data from leading companies. Appreciative of the market state by amenability of correct historical data regarding each and every sector for the forecast period is mentioned. Driving forces, restraints, and opportunities are given to help give an improved picture of this market investment for the forecast period of 2021 to 2027.

The main questions answered in the report are:

Table of Contents

Global Cord Blood Stem Cells Market Research Report 2020-2027

Chapter1Global Economic Impact on Industry

Chapter2Cord Blood Stem Cells Market Overview

Chapter3Global Market Competition by Manufacturers

Chapter4Global Production, Revenue (Value) by Region

Chapter5Global Supply (Production), Consumption, Export, Import by Regions

Chapter6Global Production, Revenue (Value), Price Trend by Type

Chapter7Global Market Analysis by Application

Chapter8Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter9Manufacturing Cost Analysis

Chapter10Global Cord Blood Stem Cells Market Forecast

Chapter11Market Effect Factors Analysis

Chapter12Marketing Strategy Analysis, Distributors/Traders

Buy Exclusive Report @

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. SMR Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information, and analysis on the sector of your interest.

Contact Us:Email

Here is the original post:

Global Cord Blood Stem Cells Market to 2026 Industry Perspective, Comprehensive Analysis, and Forecast KSU | The Sentinel Newspaper - KSU | The...

Read more
Axion BioSystems Announces Formation of Scientific Advisory Board – BioSpace

ATLANTA--(BUSINESS WIRE)-- Axion BioSystems, a leading life science tools company focused on developing and commercializing label-free, bioelectronic assays used to study the function of live cells in vitro, announces the formation of a Scientific Advisory Board (SAB). The SAB will be chaired by Jim Ross, Ph.D., founder and Chief Technology Officer, and will work closely with Axion BioSystems management team to help identify and prioritize Axions next generation of bioelectronic products.

We are proud to have such an accomplished and diverse group of scientific experts joining our Scientific Advisory Board. The SABs expertise will be invaluable as we continue expanding our research and development activities, said Tom OBrien, CEO & President of Axion BioSystems.

The members of Axion BioSystems Scientific Advisory Board include:

Christopher Basler, Ph.D., is Professor and Director of the Center for Microbial Pathogenesis at Georgia State University. He obtained his Ph.D. from Albert Einstein College of Medicine in 1995. He became Professor of Microbiology at Icahn School of Medicine at Mount Sinai in New York City in 2013 and moved to Georgia State University in 2016. Dr Basler was elected Fellow of the American Academy of Microbiology in 2014 and was named a Georgia Research Alliance Eminent Scholar in Microbial Pathogenesis in 2016. His major research interests are understanding immune evasion and replication mechanisms of filoviruses, coronaviruses and other emerging RNA viruses.

Evangelos Kiskinis, Ph.D., is an Assistant Professor of Neurology at Northwestern University Feinberg School of Medicine, Director of the Stem Cell Core Facility, and a New York Stem Cell Foundation Robertson Investigator. He received Ph.D. from Imperial College and carried out postdoctoral training at Harvard University where he pioneered the first models of ALS using personalized stem cell-based approaches. Dr Kiskinis discoveries on excitability deficits in patient neurons using induced pluripotent stem cells (iPSCs) led to a clinical trial with a small molecule drug. His laboratory seeks to harness the power of pluripotent stem cells to understand how neuronal function is impaired in ALS/FTD patients and pediatric forms of epilepsy. He has been the recipient of prestigious fellowships from the European Molecular Biology Organization, the New York Stem Cell Foundation and the Charles A. King Trust Medical Foundation.

Alysson Muotri, Ph.D., is a Professor at the Departments of Pediatrics and Cellular & Molecular Medicine at UC San Diego. He is also the Director of the Stem Cell Program and Archealization Center at UCSD. His lab focuses on the re-creation of the human brain using stem cell technologies and brain organoids. Dr. Muotri received his Ph.D. in Genetics in 2001 from University of Sao Paulo, Brazil, and moved to the Salk Institute as Pew Latin America Fellow in 2002 for postdoctoral training in the fields of neuroscience and stem cell biology. His research focuses on brain evolution and modeling neurological diseases using human induced pluripotent stem cells and brain organoids. He has received several awards, including the prestigious NIH Directors New Innovator Award, NARSAD, Emerald Foundation Young Investigator Award, Surugadai Award, Rock Star of Innovation, NIH EUREKA Award, Telly Awards among several others.

Manu Platt, Ph.D., is a Professor at the Wallace H. Coulter Department of Biomedical Engineering at Georgia Institute of Technology & Emory University. He received his Ph.D. from Georgia Tech/Emory joint program in Biomedical Engineering, and carried out postdoctoral training at MIT. Currently, his lab focuses on pediatric strokes in sickle cell disease and personalized and predictive medicine strategies for breast cancer. Dr Platts work has been successfully funded by NIH Directors New Innovator Award, International AIDS Society, Georgia Cancer Coalition, and the National Science Foundation. Dr. Platt was inducted as inducted as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) in 2019. Integrated with his research program are his mentoring goals of changing the look of the next generation of scientists and engineers to include all colors, genders, and backgrounds. Aligned with that goal, Dr. Platt co-founded Project ENGAGES (Engaging the Next Generation At Georgia Tech in Engineering and Science), with Dr. Bob Nerem in 2013.

Jiwen Zhang, Ph.D., is Vice President of Regulatory Affairs at Passage Bio, Inc. Before joining Passage Bio, she had worked at Tmunity, GE Healthcare and biopharmaceutical companies including Johnson & Johnson, Merck, Wyeth Pharmaceuticals, and Sanofi-Aventis. Dr. Zhang has extensive experience in regulatory development across multiple therapeutic areas, including anti-inflammatory, anti-viral, metabolic, hematology, bone and growth. She has also had experience in developing drug/device combination products, and medical devices used at cell therapy point of care setting. She is leading various industry initiatives through the Standards Coordinating Body, the International Standards Organization (ISO), CASSS, and Asia Pacific Economic Cooperation Regulatory Harmonization Steering Committee (APEC RHSC). Dr. Zhang obtained her Ph.D. in Neuroscience from the joint program at the Rutgers University and the University of Medicine and Dentistry of New Jersey.

For more information, please visit

About Axion BioSystems, Inc.

Axion, a life science company located in Atlanta, GA, developed the first commercial multi-well MEA system, the Maestro, an easy-to-use, non-invasive instrument that measures functional electrical signals from brain and heart cells. Axion have continued to expand on the promise of these label free, bioelectronic assays. Recently, Axion introduced the Maestro Z and ZHT systems, providing functional measures of cell growth, with specific applications in immuno-oncology and virology. Axions products are used by pharmaceutical and biotech companies, governmental agencies, and universities for disease modeling, drug safety, and drug discovery assays.

View source version on

View post:

Axion BioSystems Announces Formation of Scientific Advisory Board - BioSpace

Read more
Rinri Therapeutics Raises 10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss -…

SHEFFIELD, England, April 20, 2021 /PRNewswire/ --Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of 10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company's novel stem cell therapy to reverse sensorineural hearing loss (SNHL).

Rinri's underlying technology, based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield from where the company was spun out, seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. SNHL happens when there is damage to the hair cells in the cochlear and/or the auditory nerve. There are currently no pharmacological treatments available for SNHL despite the increasing number of patients that suffer from this condition globally.

Dr Simon Chandler, CEO of Rinri Therapeutics, commented: "We are very pleased to receive continuing support from existing investors alongside matched funding from the UK Future Fund. Our major investors share the vision we have for our technology to bring transformational changes to the lives of patients suffering from hearing loss, and the proceeds from this fund raising will allow us to advance our pioneering journey towards first in man clinical trials and to ultimately realise the potential of stem cell therapy to reverse sensorineural hearing loss."

Frank Kalkbrenner, Global Head of the Boehringer Ingelheim Venture Fund, added "We are delighted to continue our backing of Rinri and its pioneering approach to hearing loss, now with the added endorsement and support of the Future Fund. We believe Rinri's' technology is differentiated from other approaches to hearing loss restoration and has the potential to make a significant impact on treatment."

The UK Future Fund, launched in April 2020, issues convertible loans to private UK companies with good potential that typically rely on equity investment and are currently affected by COVID-19. The scheme is designed by UK government and delivered by the British Business Bank.

About Rinri Therapeutics

Rinri Therapeutics is a private biotechnology company developing advanced stem cell-based therapeutics to restore hearing. The company's pioneering technology seeks to reverse sensorineural hearing loss (SNHL) through the repair of the damaged cytoarchitecture in the inner ear. SNHL is estimated to affect 64 million patients in the US and 34 million in Europe. There are currently no pharmacological treatment options for SNHL patients.

Rinri, is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield. Rinri was founded in late-2018 and is headquartered in Sheffield, UK.

For more information, please visit:


Rinri Therapeutics Dr Simon Chandler, CEO [emailprotected]

Citigate Dewe RogersonSylvie Berrebi, Frazer HallE: [emailprotected] T: +44 (0)20 7638 9571

SOURCE Rinri Therapeutics

Here is the original post:

Rinri Therapeutics Raises 10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss -...

Read more
Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus – Proactive Investors USA

() specializes in developing cell-based technologies but is also involved in the management of stem-cell banks and clinical laboratories and the fight against coronavirus (COVID-19).

Via its two platforms, Avalon Cell and Avalon Rehab, thecompany develops proprietary diagnostic and therapeutic products leveraging regenerative medicine and exosome technology. It markets proprietary exosome isolation systems and related products to hospitals.

In laymans terms, exosomes are akin to powerful messengers (tiny, membrane-bound vesicles) released by cells into biofluids like plasma/serum, urine, and saliva.

Avalon says exosomes, which carry cellular proteins and genetic material, can help fight the progression of certain cancers and act as biomarkers to detect tumors through liquid biopsy tests.

The Freehold, New Jersey-based company has also developed proprietary cancer immunotherapy called CAR-T, short for chimeric antigen receptor therapy. CAR-T involves genetically modifying T-cells, specifically manufactured for each individual patient, to activate the bodys immune system to recognize and destroy cancer cells.

Avalons lead CAR-T therapy is AVA-001, which is designed to treat relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma.And the company has developed a number ofskincare and wound-healing products that use clinical-grade tissue-specific exosomes as additives.

In March 2021, Avalon announced that it will work with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center to advance the firms RNA based candidates andrelapsed/refractory B-cell lymphoblastic leukemia and non-Hodgkin lymphoma treatment, AVA-001, whichtargets tumor antigens on cancer cells.Avalon CEO David Jin has described the collaboration as a milestone in the clinical development and production of AVA-011 and other RNA-based FLASH-CAR candidates ahead of the start of the firms first-in-human clinical trials.

Avalon and the UPMC Cancer Center will co-develop and deploy Avalons new Point-of-Care (POC) Modular Autonomous Processing System (PMAPsys) onsite. This is a proprietary lab platform intended to provide POCprocess development, optimization, validation and manufacturing of clinical-grade products for cell and gene therapies at Good Manufacturing Practice (GMP) facilities.

Earlier in March, Avalon also reported that it is expanding its co-development research program with the Massachusetts Institute of Technology (MIT), involving the use of CRISPR-based genome editing and QTY protein design technology to potentially treat and prevent cancer metastasis the spreading of cancer cells from the initial tumor site to surrounding tissues and organs. Their workhas already generated a prototype device to soak up the excess chemokines and cytokines produced in the body that lead to the potentially fatal cytokine storm, which can occur in patients with COVID-19, and in cancer patients being treated with CAR T-cell therapy.

Avalon also had a busy spell in the final quarter of 2020. In October, the company forged a strategic collaboration for the global distribution of COVID-19 point-of-care antibody rapid test devices. It noted that the Assure/FaStep COVID-19 IgG/IgM Rapid Test Device is the first serology (antibody) POC test for COVID-19 using fingerstick blood samples approved by the US Food and Drug Administration (FDA).

The FDA has issued an emergency use authorization (EUA) for the test device as well as for the Assure/EcoStep COVID-19 IgG/IgM Rapid Test Device. Under the agreement, Adial has granted Avalon non-exclusive, sub-distribution rights worldwide for both tests. As a result of the FDA's EUA, fingerstick blood samples can now be utilized with the FaStep COVID-19 IgG/IgM Rapid Test Device for the test in POC settings, including doctors' offices, hospitals,or other locations where there is a healthcare professional.

In the December 2020 issue of NatureBiopharma Dealmakers, Avalons Jin, highlighted the bio-developer's ongoing scientific and clinical developments including a first-in-human trial of a mucosal, intranasal vaccine against SARS-CoV-2 that is planned for early 2021.

In September, Avalon had announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform as a potential therapy for COVID-19. The company said it believes that its MSC platform could offer a unique approach to treat the potentially fatal acute respiratory distress syndrome, multi-system inflammatory syndrome and cytokine storm-related to severe cases of COVID-19.

In addition to being a potential therapy for COVID-19, the company said the platform would also be developed to treat bone marrow transplant-related complications of acute graft versus host disease (aGVHD).

In the December Nature Biopharma Dealmakers issue, Dr Jin also described the companys innovative, MSCtherapy candidate, CB-MSC-1, which possess unique anti-inflammatory and immunomodulatory activities, as well as AVA-001, Avalons third-generation CAR T cell therapy that has shown robust activity in patients in a Phase 1 trial.

At the start of October, Avalon said it had expanded the Phase 1 clinical trial of AVA-001, to include enrollment of patients with relapsed/refractory non-Hodgkin lymphoma. AVA-001 is a chimeric antigen receptor (CAR) T-cell (a type of white blood cell) therapy and allogeneic mesenchymal stromal cell (MSC, or connective tissue) therapy, which is designed to improve the bodys capacity to kill cancer cells. Earlier in the year,Avalon had successfully completed a first-in-human trial of the drug, and found that nine out of 10 patients with relapsed/refractory B-cell acute lymphoblastic leukemia achieved complete remission within one month.

Avalon also has a partnership with the Institute for Synthetic Bioarchitectures at the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria. The collaboration melds BOKUs S-layer nanotechnology with Avalons expertise in biomanufacturing, cell therapy engineering, and clinical development. Avalon will leverage the pioneering work of Professor Uwe B. Sleytr, who is a top expert on applied surface layer (S-layer) technology, and Professor Emeritus in the Department of Nanobiotechnology at BOKU.

Professor Sleytr is also a member of Avalons Scientific and Clinical Advisory Board.Avalon and BOKU are establishing a research facility, the Christian Doppler Laboratory, on the BOKU campus.In connection with the new facility, Avalon and BOKU have signed a pact to jointly apply for a matching research grant from the Christian Doppler Laboratory Foundation.

In thestatement announcing thecollaboration with the UPMCHillman Cancer Center,Avalon CEO Dr David Jin said: "We are excited about our partnership on thenew point-of-care Modular Autonomous Processing Systemwith UPMC, which we believe will help accelerate the path to bringing our own and third-party cell therapies to market.We are working diligently to fast-track development and commercialization of our cellular immune-oncology therapeutic products, while providing the highest quality and safety standards for our patients."

Contact the author Uttara Choudhury at

Follow her on Twitter: @UttaraProactive

Read more here:

Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus - Proactive Investors USA

Read more
Global Regenerative Medicines Market 2020-2030: Opportunities in Drug Approvals and Strong Pipeline of Cell and Gene Therapies & Multiple…

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicines Market 2020-2030: Focus on Products, Applications, 17 Countries' Data and Competitive Landscape" report has been added to's offering.

The global regenerative medicines market is projected to reach $87.03 billion by 2030 and set to witness a CAGR of 13.99% from 2020 and 2030.

The market is driven by certain factors, including increasing consolidation among healthcare juggernauts, rising number of clinical trials for regenerative therapies, a favorable regulatory environment to accelerate approvals and market entry, and rising awareness for stem cell therapeutics, that are fueling the growth of the global regenerative medicines market.

Regenerative medicine is challenging the current healthcare practices by targeting the treatment of the root causes of disease and disorders, transforming it into an incredibly exciting space. However, these advancements have not come without significant challenges and uncertainties, which will also further need to be overcome to realize the full potential of regenerative medicine.

Cell and gene therapies, under the regenerative umbrella, are slowly and steadily becoming a healthcare standard, particularly in developed regions such as the U.S. and Europe, where already established markets for tissue engineering and stem cell have largely been responsible for driving the global regenerative medicine phenomenon. Cell and gene therapies, though advancing at a rapid pace, have primarily been targeted for hematological malignancies.

However, the same potential has not been replicated in solid tumor applications, consequently creating demand for cell therapies focusing on solid tumors. As a result, the industry is now moving toward the research and subsequent clinical translation of next-generation therapies, led by natural killer (NK) cells, which offer a viable option for solid tumors as well. Such trends are consistently propelling the industry toward realizing the true potential of precision medicine.

Within the research report, the market is segmented on the basis of products, applications, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The global regenerative medicines market is currently witnessing several developments, primarily aimed toward bringing new products to support clinicians for the treatment of life-threatening disorders. Major manufacturers of regenerative medicine products are actively involved in undertaking significant business strategies in order to translate success in research and development into the commercial clinical setting. Although tissue engineering and stem cells remain the dominating product segments, the advent of cell and gene therapy has revolutionized the regenerative medicine phenomenon, moving it more toward the precision medicine space.

Key Topics Covered:

Executive Summary

1 Product Definition and Market Scope

1.1 Inclusion and Exclusion

1.2 Scope of Work

1.3 Key Questions Answered in the Report

2 Research Methodology

3 Market Overview

3.1 Clinical Importance of Regenerative Medicine

3.2 Market Footprint

3.3 Impact of COVID-19

4 Market Dynamics

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing Consolidation in the Regenerative Medicines Market

4.2.2 Rising Number of Clinical Trials

4.2.3 Favorable Regulatory Environment

4.2.4 Rising Awareness for Stem Cell Therapeutics

4.3 Market Restraints

4.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy

4.3.2 Exorbitant Cost of Next-Generation Therapies

4.4 Opportunities

4.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies

4.4.2 Multiple Investments in Expansion of cGMP Units

4.4.3 Innovations in Regenerative Medicine

5 Industry Insights

5.1 Overview

5.2 Legal and Regulatory Framework in the U.S.

5.2.1 Cell and Gene Therapy Cell and Gene Therapy Manufacturing QC Product Testing Microbial Testing Identity Purity Potency Viability Cell Number/Dose

5.2.2 Stem Cell Therapy

5.2.3 Tissue-Engineered Products

5.3 Legal and Regulatory Framework in Europe

5.4 Legal and Regulatory Framework in Asia-Pacific

5.4.1 China

5.4.2 Japan

6 Global Regenerative Medicines Market: Competitive Insights

6.1 Overview

6.2 Synergistic Activities

6.3 Product Approval

6.4 Mergers and Acquisitions

6.5 Business Expansion and Funding

6.6 Product Launches and Upgradations

6.7 Market Share Analysis, 2019-2020

6.7.1 Market Share Analysis for Global Regenerative Medicines Market (Tissue Engineering), 2019-2020

6.7.2 Market Share Analysis for Global Regenerative Medicines Market (Cell and Gene Therapy), 2019-2020

6.7.3 Market Share Analysis for Global Regenerative Medicines Market (Stem Cell Therapy), 2019-2020

6.8 Growth Share Analysis

6.8.1 Growth Share Analysis (by Company)

6.8.2 Growth Share Analysis (by Product)

6.8.3 Growth Share Analysis (by Application)

7 Global Regenerative Medicines Market (by Product Type), $Million, 2019-2030

7.1 Overview

7.2 Tissue Engineering

7.2.1 Allogeneic Tissue

7.2.2 Autologous Tissue

7.2.3 Xenogeneic Tissue

7.2.4 Synthetic Tissue

7.2.5 Other Tissues

7.3 Stem Cells

7.3.1 Stem Cell Services

7.3.2 Stem Cell Therapy

7.4 Cell and Gene Therapy

7.4.1 Cell Therapy Cell Therapy (by Type)

7.4.2 Gene Therapy

8 Global Regenerative Medicines Market (by Application), $Million, 2019-2030

8.1 Overview

8.2 Orthopedic and Musculoskeletal

8.3 Oncology

8.4 Wound Care

8.5 Cardiology

8.6 Immunology

8.7 Dermatology

8.8 Other Applications

9 Global Regenerative Medicines Market (by Region), $Million, 2019-2030

10 Company Profiles

For more information about this report visit

Continue reading here:

Global Regenerative Medicines Market 2020-2030: Opportunities in Drug Approvals and Strong Pipeline of Cell and Gene Therapies & Multiple...

Read more